Alterations of tumor suppressor gene p16INK4a in pancreatic ductal carcinoma

BMC Gastroenterology

Volumn 5, Issue , 2005, Pages

  Attri, Jyotika ^a   Srinivasan, Radhika ^a   Majumdar, Siddhartha ^a   Radotra, Bishan Dass ^a   Wig, Jaidev ^a  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; MONOCLONAL ANTIBODY; PROTEIN P16INK4A; CYCLIN DEPENDENT KINASE INHIBITOR 2A;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DNA METHYLATION; DNA SEQUENCE; FEMALE; GENE DELETION; GENE INACTIVATION; GENE LOSS; GENE MUTATION; GENE SEQUENCE; GENETIC CODE; HOMOZYGOSITY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PANCREAS ADENOCARCINOMA; PANCREAS DUCT; POLYMERASE CHAIN REACTION; PROMOTER REGION; PROTEIN EXPRESSION; SINGLE STRAND CONFORMATION POLYMORPHISM; TUMOR SUPPRESSOR GENE; ADENOCARCINOMA; GENE SILENCING; GENETICS; HOMOZYGOTE; METABOLISM; METHODOLOGY; MIDDLE AGED; MUTATION; PANCREAS CARCINOMA; STAINING;

ADENOCARCINOMA; ADULT; AGED; CARCINOMA, PANCREATIC DUCTAL; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA METHYLATION; FEMALE; GENE DELETION; GENE SILENCING; GENES, P16; HOMOZYGOTE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MUTATION; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; PROMOTER REGIONS, GENETIC; STAINING AND LABELING;

EID: 26444580829     PISSN: 1471230X     EISSN: 1471230X     Source Type: Journal    
DOI: 10.1186/1471-230X-5-22     Document Type: Article

References (38)

1. Torrisani J, Buscail L: Molecular pathways of pancreatic carcinogenesis. Ann Pathol 2002, 22:349-55.
2. Serrano M, Hannon GJ, Beach D: A new regulatory motif in cell cycle control causing specific inhibition of cycling D/CDK4. Nature 1993, 366:704-707.
3. Cobrinik D, Dowdy SF, Hinds PW, Mittnacht S, Weinberg RA: The retinoblastoma protein and the regulation of cell cycling. Trends Biochem Sci 1992, 17:312-315.
4. De Vos S, Miller CW, Takeuchi S, Gombart AF, Cho SK, Koeffler HP: Alterations of CDKN2 (p16) in Non-small cell lung cancer. Genes Chromosomes Cancer 1995, 14:164-170.
5. Hatta Y, Hirama T, Takeuchi S, Lee E, Pham E, Miller C, Strohmeyer T, Wilczynski S, Melmed S, Koeffler H: Alteration of p16 gene intesticular, ovarian and endometrial malignancies. J Urol 1995, 154:1954-1957.
6. Kamb A, Gruis NA, Weaver-Feldhaous J, Liu Q, Harshman K, Tavtigian SV, Stockert B, Day RS, Johnson BE, Skolnick MH: A cell cycle regulator potentially involved in genesis of many tumor types. Science 1994, 264:436-440.
7. Caldas C, Hahn SA, daCosta LT, Redston MS, Schutte M, Seymour AB, Weinstim CL, Hruban RH, Yeo CJ, Kern SE: Frequent somatic mutations and homozygous deletions of p16 (MTSI) gene in pancreatic adenocarcinoma. Nat Genet 1994, 8:27-31.
8. Nobori T, Miura K, Wu DJ, Lois A, Takabayashi K, Carson DA: Deletion of cyclin dependent kinase-4 inhibitor gene in multiple human cancers. Nature 1994, 368:753-756.
9. Okajima E, Fukuda T, Okita S, Tsutsumia M, Hirao Y, Konishi Y: In frequent somatic alteration of p16/MTS1 in human primary superficial bladder cancer. Cancer Lett 1996, 103:227-231.
10. Pollock PM, Pearson JU, Hayward NK: Compilation of somatic mutation of CDKN2 gene in human cancers: non random distribution of base substitutions. Genes Chromosomes Cancer 1996, 15:77-88.
11. Merlo A, Herman JG, Mao L, Lee DJ, Gabrielson E, Burger PC, Baylin SB, Sidranski D: 5' CpG island methylation is associated with transcriptional silencing of tumor suppressor p16 / CDKN2 / MTS1 in human cancers. Nat Med 1995, 1:686-692.
12. Baylin SB, Herman JG, Graff JR, Vertino PM, Issa JP: Alterations in DNA methylation : a fundamental aspect of neoplasia. Adv Cancer Res 1998, 72:141-196.
13. Huang L, Goodrow TL, Zhang SY, Klein Szanto AJP, Chang H, Ruggeri BA: Deletion and mutation analysis of the p16/MTS-1 tumor suppressor gene in human ductal pancreatic carcinoma reveals higher frequency of abnormalities in tumor derived cell lines than in primary ductal adenocarcinomas. Cancer Res 1996, 56:1137-1141.
14. INK4a, p53, MDM2 and Rb. Ann Surg 2002, 235:51-59.
15. Ohtsubo K, Watanabe H, Yamaguchi Y, Hu YX, Motto Y, Okai T, Sawabu N: Abnormalities of tumor suppressor gene p16 in carcinoma: Immunohistochemical and genetic findings compared with clinicopathological parameters. J Gastroenterol 2003, 38(7):663-671.
16. Zhonghua Yi, Xue Yi, Chuan Xue, Yuan Xue, Za Zhi: Study on the relationship on alterations and expression of p16 gene to pancreatic carcinoma. Article in Chinese 2000, 17:399-403.
17. Moore PS, Orlandini S, Zamboni G, Capelli P, Rigaud G, Falconi M, Bassi C, Lemoine NR, Scarpa A: Pancreatic tumors: molecular pathways implicated in ductal cancer are involved in ampullary but not in exocrine non-ductal or endocrine tumorigenesis. Br J Cancer 2001, 84:253-262.
18. Sobin LH, Wittekind CH: TNM classification of malignant tumors. 5th edition. Wiley Liss:New York; 1997:87-90.
19. Hayashi K: PCR-SSCP: a simple & sensitive method for detection of mutation in the genomic DNA. PCR Methods Appl 1991, 1:34-38.
20. Bassam BJ, Caetano-Anolles, Greschoff PM: Fast and sensitive silver staining of DNA in polyacylamide gels. Anal Biochem 1991, 196:80-83.
21. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB: Methylation specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 1996, 93:9821-9826.
22. Jiang W, Zhang YJ, Kahn SM, Hollstein MC, Santella RM, Lu SH, Harris CC, Montesano R, Weinstein IB: Altered expansion of cyclin D1 and retinoblastoma genes in human osophageal cancer. Proc Natl Acad Sci USA 1993, 90:9026-9030.
23. He J, Allen JR, Collins VP, Allalunis-Turner MJ, Godbout R, Day RS, James CD: CDK4 amplification is an alternative mechanism of p16 gene homozygous deletion in glioma cell lines. Cancer Res 1994, 54:5804-5807.
24. Seymour AB, Hruban RH, Redston MS, Caldas G, Powell SM, Kinzler KW, Yeo CH, Kern SE: Allelotype of pancreatic adenocarcinoma. Cancer Res 1994, 54:9761-64.
25. Barton CM, Mckie AB, Hogg A, Bia B, Elia G, Phillips SMA, Ding SF, Lemoine NR: Abnormalities of the RB1 and DCC tumor suppressor gene: uncommon in human pancreatic adenocarcinoma. Mol Carcinog 1995, 13:61-69.
26. Rozenblum E, Schutte M, Goggins M, Hahn SA, Panzer S, Zahurak M, Goodman SN, Sohn TA, Hruban RH, Yeo CJ, Kern SE: Tumor suppressive pathways in pancreatic carcinoma. Cancer Res 1997, 57:1731-34.
27. Schutte M, Hruban RH, Geradts J, Maynard R, Hilgers W, Rabindran SK, Hahn SA, Moskaluk CA, Waldhoff IS, Schmiegel W, Baylin SB, Kern SE, Herman JG: Abrogation of the Rb/p16 tumor suppressor pathway in virtually all pancreatic carcinomas. Cancer Res 1997, 57:3126-3130.
28. INK4a mutations from primary tumors. JNCI 1999, 91:1569-1574.
29. Ravnik-Glavac M, Glavac D, Dean M: Sensitivity of single strand conformation polymorphisms and heteroduplex method for mutation detection in the cystic fibrosis gene. Hum Mol Genet 1994, 3:801-807.
30. Fukushima N, Sato N, Ueki T, Rosty C, Walter KM, Wilentz RE, Yeo CJ, Hruban RJ, Goggins M: Aberrant methylation of preproenkephalin and p16 genes in pancreatic intraepithelial neoplasia and pancreatic ductal adenocarcinoma. Am J Pathol 2002, 160:1573-1581.
31. Shen L, Ahuja N, Shen Y, Habib NA, Toyota M, Rashid A, Issa JPJ: DNA methylation and environmental exposures in human hepatocellular carcinoma. JNCI 2002, 94:755-761.
32. Ueki T, Toyota M, Sohn T, Yeo CJ, Issa JPJ, Hruban RH, Goggins M: Hypermethylation of multiple genes in pancreatic adenocarcinoma. Cancer Res 2000, 60:1835-1839.
33. Wilentz RE, Geradts J, Maynard R, Offerhaus GJA, King M, Goggins M, Yeo CJ, Kern SE, Hruban RH: Inactivation of p16INK4a tumor suppressor gene in duct lesions: loss of intranuclear expression. Cancer Res 1998, 58:4740-4744.
34. INK4a alteration in chronic pancreatitis - indicator for high risk lesions for pancreatic cancer. Surgery 2001, 129:490-497.
35. Klump B, Hsieh CJ, Nehls O, Dette S, Holzmann K, Kiesslich I, Jung M, Sinn U, Ortner M, Porschen R, Gregor M: Methylation status of p14ARF and p16INK4a as detected in pancreatic secretions. Br J Cancer 2003, 88:217-222.
36. Bartsch D, Shevlin DW, Callery MP, Norton JA, Wells SA Jr, Goodfellow PJ: Reduced survival in patients with ductal pancreatic adenocarcinoma associated with CDKN2 mutation. J Natl Cancer Inst 1996, 88:680-682.
37. Hu YX, Watanabe H, Ohtsubo K, Yamaguchi Y, Ha A, Okai T, Sawasu N: Frequent loss of p16 expression and its correlation with clinicopathological parameters in pancreatic carcinoma. Clin Cancer Res 1997, 3:1473-1477.
38. Naka T, Kobayashi M, Ashida K, Toyota N, Kaneko T, Kaibara N: Aberrant p16INK4 expression related to clinical stage and prognosis in patients with pancreatic cancer. Int J Oncol 1998, 12:1111-1116.